Mount Gambier resident Ben Whitehead in remission after surprise cancer trial results
Ben Whitehead, a resident of Mount Gambier, has entered remission for stage four peripheral T-cell lymphoma following participation in clinical trials at Monash University and the Peter MacCallum Cancer Centre. Whitehead, who is the only known person in Australia with this specific type of cancer, was given three months to live in October 2025, according to reports from the ABC.
The remission follows a second targeted therapy trial that began in January. Whitehead reported that his previous treatment at the Peter MacCallum Cancer Centre was halted after scans revealed new cancer cells, leading his doctor, Philip Thompson, to suggest the Monash University trial.
How did targeted therapy achieve these results?
The treatment used is a targeted therapy rather than an immunotherapy. According to Whitehead, the therapy functions by linking itself to the protein the cancer grows on, making that protein unavailable and effectively starving the cancer cells.
Medical teams utilized genetic sequencing to facilitate this process. Whitehead stated that doctors run genetic sequencing of cancers through databases to tailor specific drugs for different types of cancer.
What were the financial implications of the treatment?
The process of seeking specialized care created significant financial strain. Whitehead stated that his “nest egg,” intended for a car or holidays, was quickly consumed by the costs associated with his care.
Beyond direct medical costs, the logistics of the trials required Whitehead to live in Melbourne for six months. He will continue to travel to Melbourne once a month to receive ongoing treatment.
What may happen next for the patient?
Whitehead plans to document his experience and the use of humor during his illness in a book. He has previously used social media to share his journey and encourage others to seek second opinions.
Medical monitoring is likely to continue through his monthly visits to Melbourne. Future outcomes may depend on the continued efficacy of the targeted therapy in preventing the recurrence of cancer cells.
Frequently Asked Questions
What is the difference between the therapy Ben Whitehead received and immunotherapy?
According to Whitehead, the treatment is a targeted therapy that starves the cancer by blocking the protein it grows on, rather than using immunotherapy.
Which institutions provided the clinical trials?
Whitehead received treatment at the Peter MacCallum Cancer Centre and Monash University.
When was the initial diagnosis and prognosis delivered?
Whitehead noticed significant health changes in October 2025 and was subsequently given three months to live.
How do you feel about the role of clinical trials in treating rare medical conditions?